UNSPSC 51434921: Flumethiazide/potassium chloride/rauwolfia serpentina

This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class CV400. This VA Drug Class (CV400) classifies this compound as belonging to the group ANTIHYPERTENSIVE COMBINATIONS.

UNSPSC 51434921 Flumethiazide/potassium chloride/rauwolfia serpentina is a Commodity code that does not reflect the pharmaceutical procurement activity currently posted under it by state and local issuing bodies. The recent opportunities tagged to this code are solicitations for advanced life support medications (epinephrine, adenosine, diltiazem, labetalol), generic multi-source pharmaceuticals through a cooperative purchasing vehicle, and a direct-to-manufacturer prescription initiative — none of which involve the specific combination drug named in the code. The mismatch suggests the code classification in the source data does not align with actual procurement scope. State and local governments soliciting under this code designation are pursuing pharmaceutical supply agreements through city fire-rescue services, state health departments, and multistate cooperative purchasing alliances (MMCAP), with issuing bodies including municipal purchasing departments (City of Tampa), state health agencies (Texas Health and Human Services Commission), and collaborative procurement offices (Minnesota Department of Administration).

Recent activity spans Florida, Texas, and Minnesota. The City of Tampa issued IFB 26P00188 for advanced life support medications with a response date of April 8, 2026 and an estimated contract value of $40,000, requiring four specific medication line items with nine-month minimum expiration dates and one-year firm pricing with optional renewal periods, and offering a 5 percent bid discount for Small Local Business Enterprise participation. The Texas Health and Human Services Commission posted RFI HHS0017013 on April 3, 2026 as a preliminary information-gathering mechanism to assess vendor capacity for direct-to-manufacturer prescription contracting outside traditional pharmacy benefit manager and group purchasing organization channels. The Minnesota Department of Administration's Office of State Procurement, administering MMCAP, issued an RFP posted January 20, 2026 with a response deadline of March 26, 2026 for generic multi-source pharmaceuticals and OTC products to be distributed across participating state and local government facilities in Minnesota and Oregon, with awarded vendors effective July 1, 2026 and contract terms of two years with optional extensions.